Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation.
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation.
复制标题
HPV-16/18 AS04辅助疫苗对低风险HPV类型（Patricia随机试验）的功效：意外观察。
DOI：
10.1093/infdis/jit360
复制
发表时间：
2013-11-01
期刊：
影响因子：
--
通讯作者：
Dubin G
中科院分区：
文献类型：
--
作者：
Szarewski A;Skinner SR;Garland SM;Romanowski B;Schwarz TF;Apter D;Chow SN;Paavonen J;Del Rosario-Raymundo MR;Teixeira JC;De Carvalho NS;Castro-Sanchez M;Castellsagué X;Poppe WA;De Sutter P;Huh W;Chatterjee A;Tjalma WA;Ackerman RT;Martens M;Papp KA;Bajo-Arenas J;Harper DM;Torné A;David MP;Struyf F;Lehtinen M;Dubin G
背景。英国公共卫生部报告说，自从2008年开始实施人乳头瘤病毒(HPV)-16/18 as04佐剂疫苗的国家疫苗接种计划以来，19岁以下妇女外阴疣（GWs）的新诊断减少了20.8%。对III期PATRICIA（年轻成人抗癌症乳头瘤试验）试验（NCT00122681）进行了事后分析，以确定对低风险HPV类型的保护是否明显。方法。48个月时的疫苗效力（VE）在总接种队列（TVC）和TVC初始（25种HPV类型测试）人群中针对6个月低风险HPV型持续感染（6MPI）进行评估。结果。在TVC初始队列中，HPV-6/11对6MPI的VE（95%置信区间）为34.5% (11.3 ~ 51.8)，HPV-6为34.9% (9.1 ~ 53.7)，HPV-11为30.3% (- 45.0 ~ 67.5)，HPV-74为49.5%（21.0 ~ 68.3）。结论。HPV-16/18 as04佐剂疫苗似乎对许多低风险HPV类型（HPV-6/11/74）的持续感染具有中等疗效，这些类型是导致大多数外部GWs的原因，最近已经观察到针对HPV-6/11的抗体和细胞介导的免疫反应。这些发现可能有助于解释英国外部GW诊断的减少。
Background. Public Health England has reported a decrease of up to 20.8% in new diagnoses of external genital warts (GWs) among women aged <19 years since the national vaccination program with the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine began in 2008. A post hoc analysis of the phase III PATRICIA (PApilloma TRIal against Cancer In young Adults) trial (NCT00122681) was performed to ascertain whether protection against low-risk HPV types was apparent. Methods. Vaccine efficacy (VE) at 48 months was assessed against 6-month persistent infection (6MPI) with low-risk HPV types in the total vaccinated cohort (TVC) and in the TVC naive (for 25 HPV types tested) populations. Results. In the TVC naive cohort, VE against 6MPI (95% confidence interval) was 34.5% (11.3 to 51.8) for HPV-6/11, 34.9% (9.1 to 53.7) for HPV-6, 30.3% (−45.0 to 67.5) for HPV-11, and 49.5% (21.0 to 68.3) for HPV-74. Conclusions. The HPV-16/18 AS04-adjuvanted vaccine appears to have moderate efficacy against persistent infections with a number of low-risk HPV types (HPV-6/11/74), which are responsible for the majority of external GWs, and recently, antibody and cell-mediated immune response to HPV-6/11 have been observed. These findings may help to explain the decrease in external GW diagnoses seen in England.
登录
查看更多内容
影响因子：
1.4
作者：
Lanitis, T.;Carroll, S.;Brown, R. E.
通讯作者：
Brown, R. E.
DOI：
10.4161/hv.7.12.18281
发表时间：
2011-12-01
期刊：
HUMAN VACCINES
影响因子：
--
作者：
Einstein, Mark H.;Baron, Mira;Dubin, Gary
通讯作者：
Dubin, Gary
影响因子：
51.1
作者：
Wheeler, Cosette M.;Castellsague, Xavier;Lehtinen, Matti
通讯作者：
Lehtinen, Matti
影响因子：
11.8
作者：
Aubin, Francois;Pretet, Jean-Luc;Riethmuller, Didier
通讯作者：
Riethmuller, Didier
影响因子：
3.6
作者：
Pirotta, M.;Ung, L.;Garland, S.
通讯作者：
Garland, S.